Item 2.02 - Results of Operations and Financial Condition: The filing reports Humana Inc.'s results of operations and financial condition as of February 11, 2026 Item 7.01 - Regulation FD Disclosure: The company is making a Regulation FD disclosure, indicating material information is being disclosed to investors Item 9.01 - Financial Statements and Exhibits: The filing includes financial…

Our analysis rates this filing BEARISH. Humana faces a HIGH concern level (7.2/10) driven by multiple converging negative signals that indicate material near-term earnings deterioration and structural profitability challenges. The 9.6% year-over-year EPS guidance decline is explicitly quantified…

Concern level: HIGH (7.2/10). Key factors: Material earnings guidance decline: FY 2026 GAAP EPS guidance of $8.89 represents 9.6% year-over-year decline from $9.84 actual in FY 2025, explicitly attributed to Star Ratings headwind (severity 9); Quarterly net loss in 4Q25: $6.61 GAAP loss per share and $3.96 adjusted loss per share indicates significant operational deterioration in most recent…

Notable risk changes: Material Earnings Decline Guidance: FY 2026 EPS guidance of 'at least $8.89' GAAP (vs. $9.84 in FY 2025) represents 9.6% year-over-year decline explicitly attributed to Star Ratings headwind. This is a quantified, material negative event that directly impacts shareholder returns.; Quarterly Net Loss in 4Q25: Company reported net loss per share of $6.61 GAAP and $3.96 Adjusted in most recent…

The model predicts HUM will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.